For sales

📢Highlights from the Week of 4th -11th August, 2025   in the world of pharma and healthcare! 🗞️👀

Highlights from the Week of 4th -11th August, 2025 Jazz Pharmaceuticals ( FDA, Approval ) FDA approved Jazz Pharmaceuticals' MODEYSO (dordaviprone) for the treatment of recurrent H3 K27M-mutant diffuse midline glioma Celltrion ( FDA, Approval ) FDA approved Celltrion's expanded indication for AVTOZMA (biosimilar version of ACTEMRA) intravenous (IV) for the treatment of cytokine release syndrome (CRS) Boehringer Ingelheim ( FDA, Approval ) FDA granted accelerated approval to Boehringer's HERNEXEOS® for patients with HER2-mutant advanced NSCLC who have undergone treatment Teva Pharmaceuticals ( FDA , Approval ) FDA approved an expanded indication for Teva's AJOVY (fremanezumab-vfrm) for pediatric patients suffering from episodic migraine All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.